
SERVICES

Convex Clinical Research Center is a leading First-in-Human (FIH) and Phase I research institution in Eastern Europe, with more than 34 years of experience and over 450+ successfully completed clinical trials. Our dedicated team and state-of-the-art Phase I infrastructure support biotech and pharmaceutical companies in accelerating their early-phase drug development programs.
Always-On Sponsor Communication
Dedicated Clinical Research Site
Expert Early-Phase Research Team
450+ Completed Clinical Trials
Fastest Regional Study Start-Up
Large Volunteer & Patient Database
Integrated CRO & Site Services
Exceptional Cost Efficiency
We deliver clinical studies with full transparency, operational excellence, and speed – without compromising quality or data security. Our structured approach and proven expertise provide confidence at every step, trusted by sponsors across the industry.

SHORT TIMELINES
Timelines are set based on how studies actually run, not assumptions, allowing a reliable and predictable study start.
FULL MEDICAL CONTROL
Medical oversight remains hands-on throughout the study, with decisions made by experienced physicians, not committees.
ONE CONTRACT. ONE CLINICAL STUDY
One clear contract covers the entire study, avoiding unnecessary layers, delays, and administrative back-and-forth.
PLANNED RECRUITMENT. ACHIEVED IN TIME.
Recruitment plans reflect real availability and are delivered within the timelines agreed at study start.
Convex has extensive experience in early-phase clinical development, including First-in-Human, SAD, MAD, PK/PD, DDI, food-effect, and vaccine studies. Our Phase I unit has successfully conducted over 6-8 clinical studies in early phase development on a yearly basis. Many involving novel compounds and complex early-phase protocols. This depth of experience allows us to anticipate operational and medical risks on time.
Medical oversight at Convex is continuous and on-site. Dose administration, escalation decisions, and safety assessments are overseen by experienced Principal Investigators and clinical pharmacologists with dedicated early-phase expertise. Medical decisions are taken in real time, based on emerging safety and PK data, ensuring a high level of control during Phase I dosing.
Risk management at Convex starts during protocol review and continues throughout study execution. We routinely apply sentinel dosing, staggered dosing, conservative escalation steps, and predefined stopping rules. Early safety and PK data are carefully reviewed before progressing to subsequent cohorts, reducing cumulative exposure risk in First-in-Human trials.
Yes. Convex provides integrated CRO and Phase I site services under one structure. This model reduces coordination risk, accelerates timelines, and improves overall study control. Sponsors benefit from a single accountable partner for early-phase clinical operations, regulatory support, medical oversight, and execution.
Convex is designed for rapid study start-up. Our purpose-built Phase I infrastructure, established SOPs, and experienced start-up teams allow efficient progression from feasibility to first dosing. Integration of CRO and site activities eliminates delays commonly caused by multi-vendor coordination.
Convex operates a purpose-built Phase I clinical research unit with 24/7 medical coverage, emergency readiness, and intensive safety monitoring. The facility supports high-frequency sampling, complex early-phase protocols, and advanced cardiology and pulmonology assessments required in modern Phase I trials.
Convex maintains a large, well-characterized database of healthy volunteers and patient populations. Recruitment timelines are based on historical performance rather than optimistic assumptions. Screening strategies are designed to minimize screen failures and support tight cohort schedules in early-phase clinical trials.
Convex provides early scientific and operational input during feasibility and protocol development. This includes dose selection strategies, escalation schemes, visit schedules, and safety assessments. Early involvement helps sponsors avoid protocol amendments and operational delays during Phase I execution.
Convex operates under a robust Quality Management System aligned with ICH GCP and EU regulatory requirements. Internal QA oversight, inspection-ready documentation, and strict data integrity principles are embedded in daily early-phase operations.
Communication at Convex is proactive, transparent, and medically driven. Sponsors receive early signals and clear interpretation of emerging data. This approach supports informed decision-making during high-uncertainty Phase I studies.
Biotech companies choose Convex not only for Phase I execution, but as a strategic partner supporting progression into Phase Ib and Phase II. Our integrated model, experienced Phase I teams, and focus on controlled development make Convex a reliable long-term partner for early clinical programs.
This is the most crucial step for any biotech company. Choosing the right CRO partner is crucial for the success of your drug development journey, especially when it comes to the pivotal FIH trial. Your clinical research partner should meet the following criteria: previous experience and expertise, prioritizes participant safety, focus on scientific excellence and accurate clinical data collection. The clinical vendor shall have also a robust project management team, operational and technological capabilities to implement the requested trial design.
We meet them all!
Our teams in science, regulations, and medical writing can assist with one study or entire clinical research program. We have experts who can support you. We start from tasks like an Investigator’s Brochure (IB) preparation, getting ready for pre-IND meetings, submitting INDs, preparing CTAs, advising on study designs, and writing study protocol. All-in-one services we provide make sure your First-in-Human study starts quicker.
For the bioanalytical component of our study, we prefer partnering with Anapharm Bioanalytics. They provide extensive bioanalytical services to the pharmaceutical, biotech, and generic drug industries globally. Their laboratory is GLP-certified, FDA-inspected, GCP-compliant, and ANVISA-certified, featuring a robust quality system to ensure the delivery of consistent, reproducible, and reliable data essential for international regulatory submissions. With over 30 years of experience in analytical method development, validation, and sample analysis of both small and large molecules, they utilize advanced LC-MS/MS and Ligand Binding Assay (LBA) technology platforms across various biological matrices.
Typically, participants in First-in-human trials are healthy young men, generally between 20 and 40 years old. The selection ensures a more uniform group for investigating the effects of the new drug and reducing variability in the same time. In parallel, these group of healthy subjects are more likely to handle any unforeseen side effects from the drug being investigated. Healthy subjects are those without any health issues that could disrupt the study conduct, complicate the safety or pharmacokinetic data analysis.
The very first step to FIH clinical trial is IP formulation development. Our experts at Convex can support you throughout our CDMO partners to formulate your preferred dosage form of your investigational product. Simpler dosage forms the better.
We use Fully integrated Electronic Data Capture (EDC) system to ensure participant safety, and the accurate, timely collection of your data.
The aim of First-in-Human (FIH) trials is to find a safe first dose and other important parameters. These trials often start with healthy volunteers receiving only one dose. The investigational dose goes up slowly among different study subjects’ cohorts (called a single ascending dose or SAD study) to see the highest safe dose or any side effects that stop us from increasing the dose further. We usually perform interim analysis of safety data prior to move on to the next dose escalation. After maximum tolerated dose is identified, we move on to the next stage – Multiple Ascending Dose (MAD) study.
In Multiple Ascending Dose (MAD) study the drug is administered multiple times, which support the body reach a steady stat. Again the focus is also at safety and tolerability.
In a First-in-Man (FIM) study, the period a participant stays at the Research unit can vary. It depends on the study protocol and the specific requirements of the trial. Typically, study participants may stay at the investigational site for a few days to a couple of weeks for observation and monitoring after receiving the investigational drug. However, this duration can vary greatly depending on factors such as the nature of the drug being tested, the study design, and the need for intensive monitoring for any potential adverse reactions or side effects. We have run FIM study, whereas healthy volunteers spent 21 on-site days.
We have conducted clinical trials using different methods of delivering investigational products, such as oral, intravenous, intraperitoneal, and transdermal administration, ensuring rapid access. Convex clinical team have also been involved in studies examining the cumulative effects of investigational products.
Study population selection
We need to clearly define the specific requirements for healthy volunteers’ participation and integrate very strict inclusion/exclusion criteria.
Define the number of subjects per each cohort
The number of participants in each group is determined by how much the PK (pharmacokinetics) and PD (pharmacodynamics) parameters vary, as well as the goals of the clinical study
Dosing
Dose selection / Route of administration / Dose escalation
Stopping rules
The clinical study protocol should outline clear rules for when dosing should be stopped immediately, whether it’s a temporary pause or permanent cessation
Safety monitoring
Define strictly the process of reporting adverse events and suspected unexpected serious reactions (SUSARs), among the sponsor and study site.
Inclusion of a placebo
We speed up the beginning of your FIH trial by starting the planning process for study setup even while your preclinical IND/CTA is being reviewed by regulators. Once the review is done and your study gets the green light from the necessary regulatory bodies, your clinic activities can kick off right away.
One common cause of early drug failure is unforeseen IP toxicity, often linked to the pharmacokinetic (PK) properties of the drug. Unfortunately, this aspect is frequently overlooked. This is why Sponsoring companies of FIM trials should look carefully into preclinical data before entering in human stage.